Doubly phosphorylated peptide vaccines to protect transgenic P301S mice against Alzheimer's disease like tau aggregation

Vaccines

Volumn 2, Issue 3, 2014, Pages 601-623

  Richter, Monique ^a   Mewes, Agneta ^a   Fritsch, Manuela ^a   Krügel, Ute ^a   Hoffmann, Ralf ^a   Singer, David ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimer's disease; Immunization; P301S mice; Peptide vaccine; Phospho tau; Transgenic mouse model

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; PEPTIDE VACCINE; PLACEBO; TAU INTERFERON;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION;

EID: 84986580036     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2030601     Document Type: Article

References (60)

1. Miniño, A.M.; Xu, J.; Kochanek, K.D. Deaths: Preliminary Data for 2008. In National Vital Statistics Reports; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010; Volume 59.
2. Selkoe, D.J. Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 1989, 58, 611-612.
3. Selkoe, D.J. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993, 16, 403-409.
4. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913-4917.
5. Kosik, K.S.; Joachim, C.L.; Selkoe, D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1986, 83, 4044-4048
6. Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 1986, 83, 4040-4043.
7. Mandelkow, E.-M.; Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012, 2, doi:10.1101/cshperspect.a006247.
8. Wang, W.; Fan, L.; Xu, D.; Wen, Z.; Yu, R.; Ma, Q. Immunotherapy for Alzheimer's disease. Acta Biochim. Biophys. Sin. 2012, 44, 807-814.
9. Yoshiyama, Y.; Lee, V.M.Y.; Trojanowski, J.Q. Therapeutic strategies for tau mediated neurodegeneration. J. Neurol. Neurosurg. Psychiatry 2013, 84, 784-795.
10. Bulic, B.; Pickhardt, M.; Mandelkow, E.-M.; Mandelkow, E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010, 59, 276-289.
11. Brunden, K.R.; Ballatore, C.; Crowe, A.; Smith, A.B.; Lee, V.M.-Y.; Trojanowski, J.Q. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. Exp. Neurol. 2010, 223, 304-310.
12. Delrieu, J.; Ousset, P.J.; Caillaud, C.; Vellas, B.-Clinical trials in Alzheimer's disease: Immunotherapy approaches. J. Neurochem. 2012, 120, 186-193.
13. Asuni, A.A.; Boutajangout, A.; Quartermain, D.; Sigurdsson, E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27, 9115-9129.
14. Boimel, M.; Grigoriadis, N.; Lourbopoulos, A.; Haber, E.; Abramsky, O.; Rosenmann, H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 2010, 224, 472-485.
15. Boutajangout, A.; Ingadottir, J.; Davies, P.; Sigurdsson, E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011, 118, 658-667.
16. Boutajangout, A.; Quartermain, D.; Sigurdsson, E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 2010, 30, 16559-16566.
17. Troquier, L.; Caillierez, R.; Burnouf, S.; Fernandez-Gomez, F.J.; Grosjean, M.-E.; Zommer, N.; Sergeant, N.; Schraen-Maschke, S.; Blum, D.; Buee, L. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr. Alzheimer Res. 2012, 9, 397-405.
18. Wolf, A.I.; Mozdzanowska, K.; Williams, K.L.; Singer, D.; Richter, M.; Hoffmann, R.; Caton, A.J.; Otvos, L.; Erikson, J.; Tompkins, S.M. Vaccination with M2e-Based Multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One 2011, 6, e28445.
19. Sundaram, R.; Dakappagari, N.K.; Kaumaya, P.T.P. Synthetic peptides as cancer vaccines. Biopolymers 2002, 66, 200-216.
20. Menendez-Gonzalez, M.; Perez-Pinera, P.; Martinez-Rivera, M.; Muniz, A.L.; Vega, J.A. Immunotherapy for Alzheimer's disease: Rational basis in ongoing clinical trials. Curr. Pharm. Des. 2011, 17, 508-520.
21. Shah, S.; Federoff, H.J. Therapeutic potential of vaccines for Alzheimer's disease. Immunotherapy 2011, 3, 287-298.
22. Erb, P.; Troxler, M.; Fluri, M.; Grogg, D.; Alkan, S.S. Functional heterogeneity of CD4-positive T-cell subsets: The correlation between effector functions and lymphokine secretion is limited. Cell. Immunol. 1991, 135, 232-244.
23. Infante, A.J.; Currier, P.F. Collaboration of Th1 and Th2 T cell clones in specific antibody responses: Regulation of the IgM response to phosphorylcholine. Cell. Immunol. 1989, 122, 146-153.
24. Sigurdsson, E.M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 2004, 24, 6277-6282.
25. Raghavendra, V.; Tanga, F.Y.; DeLeo, J.A. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur. J. Neurosci. 2004, 20, 467-473.
26. Rozenstein-Tsalkovich, L.; Grigoriadis, N.; Lourbopoulos, A.; Nousiopoulou, E.; Kassis, I.; Abramsky, O.; Karussis, D.; Rosenmann, H. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 2013, 248, 451-456.
27. Bungener, L.; Geeraedts, F.; ter Veer, W.; Medema, J.; Wilschut, J.; Huckriede, A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26, 2350-2359.
28. Richter, M.; Hoffmann, R.; Singer, D. T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice. J. Pept. Sci. 2013, 19, 441-451.
29. Maurin, H.; Chong, S.-A.; Kraev, I.; Davies, H.; Kremer, A.; Seymour, C.M.; Lechat, B.; Jaworski, T.; Borghgraef, P.; Devijver, H.; et al. Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy. PLoS One 2014, 9, e87605.
30. Levenga, J.; Krishnamurthy, P.; Rajamohamedsait, H.; Wong, H.; Franke, T.F.; Cain, P.; Sigurdsson, E.M.; Hoeffer, C.A. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol. Commun. 2013, 1, doi:10.1186/2051-5960-1-34.
31. Singer, D.; Volke, D.; Hoffmann, R. Characterization of phosphorylation dependent antibodies to study the phosphorylation status of the Tau protein. Int. J. Pept. Res. Ther. 2005, 11, 279-289.
32. Yoshiyama, Y.; Higuchi, M.; Zhang, B.; Huang, S.-M.; Iwata, N.; Saido, T.C.; Maeda, J.; Suhara, T.; Trojanowski, J.Q.; Lee, V.M.-Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53, 337-351.
33. Sigurdsson, E.M.; Scholtzova, H.; Mehta, P.D.; Frangione, B.; Wisniewski, T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 2001, 159, 439-447.
34. Singer, D.; Lehmann, J.; Hanisch, K.; Hartig, W.; Hoffmann, R. Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease. Biochem. Biophys. Res. Commun. 2006, 346, 819-828.
35. Takeuchi, H.; Iba, M.; Inoue, H.; Higuchi, M.; Takao, K.; Tsukita, K.; Karatsu, Y.; Iwamoto, Y.; Miyakawa, T.; Suhara, T.; et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One 2011, 6, e21050.
36. Carter, R.J.; Morton, J.; Dunnett, S.B. Motor coordination and balance in rodents. Curr. Protoc. Neurosci. 2001, 8, doi:10.1002/0471142301.ns0812s15.
37. Bailey, K.R.; Crawley, J.N. Chapter 5 Anxiety-Related Behaviors in Mice. In Methods of Behavior Analysis in Neuroscience, 2nd ed.; Buccafusco, J.J., Ed.; CRC Press: Boca Raton, FL, USA, 2009.
38. Porzig, R.; Singer, D.; Hoffmann, R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem. Biophys. Res. Commun. 2007, 358, 644-649.
39. Hoffmann, R.; Lee, V.M.-Y.; Leight, S.; Varga, I.; Otvos, L., Jr. Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 1997, 36, 8114-8124.
40. Hiesberger, T.; Trommsdorff, M.; Howell, B.W.; Goffinet, A.; Mumby, M.C.; Cooper, J.A.; Herz, J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 1999, 24, 481-489.
41. Hanger, D.P.; Anderton, B.H.; Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009, 15, 112-119.
42. Paxinos, G.; Franklin, K.B.J. The Mouse Brain in Stereotaxic Coordinates, 2nd ed.; Academic Press: San Diego, CA, USA, 2001.
43. ImageJ, version 1.46r. U.S. National Institutes of Health: Bethesda, MD, USA, 2012.
44. Rabilloud, T. Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis 1998, 19, 758-760.
45. Shaw, M.M.; Riederer, B.M. Sample preparation for two-dimensional gel electrophoresis. Proteomics 2003, 3, 1408-1417.
46. GraphPad Prism Software, version 5.02 for Windows. GraphPad Software Inc.: San Diego, CA, USA, 2009.
47. Kaumaya, P.T.P.; Berndt, K.D.; Heidorn, D.B.; Trewhella, J.; Kezdy, F.J.; Goldberg, E. Synthesis and biophysical characterization of engineered topographic immunogenic determinants with alpha alpha topology. Biochemistry 1990, 29, 13-23.
48. Dumont, M.; Stack, C.; Elipenahli, C.; Jainuddin, S.; Gerges, M.; Starkova, N.N.; Yang, L.; Starkov, A.A.; Beal, F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 2011, 25, 4063-4072.
49. Yamada, K.; Cirrito, J.R.; Stewart, F.R.; Jiang, H.; Finn, M.B.; Holmes, B.B.; Binder, L.I.; Mandelkow, E.-M.; Diamond, M.I.; Lee, V.M.-Y.; et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 2011, 31, 13110-13117.
50. Yanamandra, K.; Kfoury, N.; Jiang, H.; Mahan, T.E.; Ma, S.; Maloney, S.E.; Wozniak, D.F.; Diamond, M.I.; Holtzman, D.M. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013, 80, 402-414.
51. Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment. Available online: http://clinicaltrials.gov/ (accessed on 2 February 2014).
52. Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients; Available online: http://clinicaltrials.gov/ (accessed on 2 February 2014).
53. Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients; Available online: http://clinicaltrials.gov/ (accessed on 2 February 2014).
54. Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease; Available online: http://clinicaltrials.gov/ (accessed on 2 February 2014).
55. Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease; Available online: http://clinicaltrials.gov/ (accessed on 2 February 2014).
56. Bi, M.; Ittner, A.; Ke, Y.D.; Götz, J.; Ittner, L.M.; Ferreira, S.T. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011, 6, e26860.
57. Chai, X.; Wu, S.; Murray, T.K.; Kinley, R.; Cella, C.V.; Sims, H.; Buckner, N.; Hanmer, J.; Davies, P.; O'Neill, M.J.; et al. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J. Biol. Chem. 2011, 286, 34457-34467.
58. Rosenmann, H.; Grigoriadis, N.; Karussis, D.; Boimel, M.; Touloumi, O.; Ovadia, H.; Abramsky, O. Tauopathy-like Abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006, 63, 1459-1467.
59. Agger, E.M.; Cassidy, J.P.; Brady, J.; Korsholm, K.S.; Vingsbo-Lundberg, C.; Andersen, P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 2008, 124, 175-185.
60. Marrack, P.; McKee, A.S.; Munks, M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9, 287-293.